Chemotherapy-induced nausea and vomiting market to reach $2.1 billion in 2018

The global chemotherapy-induced nausea and vomiting (CINV) market was worth $1.3 billion in 2011 and is expected to reach $2.1 billion in 2018, expanding at a compound annual growth rate (CAGR) of 7.1% from 2013 to 2018, according to a new market report published by Transparency Market Research.

The North American CINV existing and pipeline drugs market is expected to reach $1.0 billion in 2018. Sluggish economic growth and a poor reimbursement scenario in European countries have hampered the growth of CINV drugs market in these regions, the report notes.

Nausea and vomiting represent the most frequent side effects experienced by chemotherapy patients, which is debilitating to cancer patients. Highly emetogenic chemotherapy (HEC) mostly leads to nausea and vomiting in 90% or more of the cases, while moderately emetogenic chemotherapy (MEC) causes nausea and vomiting in 3%0-90% of the cases.